300482 万孚生物
交易中 06-22 13:25:12
资讯
新帖
简况
股市必读：万孚生物（300482）6月17日董秘有最新回复
证券之星 · 06-18
股市必读：万孚生物（300482）6月17日董秘有最新回复
万孚生物涨9.45%，信达证券一个月前给出“买入”评级
证券之星 · 06-16
万孚生物涨9.45%，信达证券一个月前给出“买入”评级
万孚生物涨15.54%，信达证券一个月前给出“买入”评级
证券之星 · 06-09
万孚生物涨15.54%，信达证券一个月前给出“买入”评级
万孚生物涨15.06%，信达证券四周前给出“买入”评级
证券之星 · 06-05
万孚生物涨15.06%，信达证券四周前给出“买入”评级
万孚生物（300482）披露万孚转债恢复转股提示性公告，6月2日股价下跌1.02%
证券之星 · 06-02
万孚生物（300482）披露万孚转债恢复转股提示性公告，6月2日股价下跌1.02%
万孚生物（300482）披露2025年年度权益分派实施公告，5月25日股价上涨0.22%
证券之星 · 05-25
万孚生物（300482）披露2025年年度权益分派实施公告，5月25日股价上涨0.22%
万孚生物：公司U-Card DX200配套的微流控芯片系公司自主设计开发及生产
证券之星 · 05-22
万孚生物：公司U-Card DX200配套的微流控芯片系公司自主设计开发及生产
万孚生物（300482）披露关于实施权益分派期间万孚转债暂停转股的提示性公告，5月21日股价下跌1.05%
证券之星 · 05-21
万孚生物（300482）披露关于实施权益分派期间万孚转债暂停转股的提示性公告，5月21日股价下跌1.05%
万孚生物（300482）披露2025年年度股东会会议决议公告，5月18日股价下跌2.21%
证券之星 · 05-18
万孚生物（300482）披露2025年年度股东会会议决议公告，5月18日股价下跌2.21%
万孚生物涨6.22%，信达证券五日前给出“买入”评级
证券之星 · 05-11
万孚生物涨6.22%，信达证券五日前给出“买入”评级
万孚生物(300482.SZ)取得一项产品注册证
智通财经 · 05-06
万孚生物(300482.SZ)取得一项产品注册证
万孚生物：万孚新一代高敏肌钙蛋白I检测试剂
证券之星 · 04-30
万孚生物：万孚新一代高敏肌钙蛋白I检测试剂
万孚生物：POCT业务是公司的基本盘
证券之星 · 04-30
万孚生物：POCT业务是公司的基本盘
万孚生物：2017年正式进军动物检测市场
证券之星 · 04-30
万孚生物：2017年正式进军动物检测市场
万孚生物（300482）2026年一季报简析：净利润同比下降55.38%
证券之星 · 04-24
万孚生物（300482）2026年一季报简析：净利润同比下降55.38%
图解万孚生物年报：第四季度单季净利润同比下降256.54%
证券之星 · 04-23
图解万孚生物年报：第四季度单季净利润同比下降256.54%
万孚生物（300482）披露召开2025年度股东会的通知，4月22日股价下跌1.08%
证券之星 · 04-22
万孚生物（300482）披露召开2025年度股东会的通知，4月22日股价下跌1.08%
万孚生物（300482）披露2026年第一季度可转换公司债券转股情况，4月3日股价下跌4.71%
证券之星 · 04-03
万孚生物（300482）披露2026年第一季度可转换公司债券转股情况，4月3日股价下跌4.71%
万孚生物（300482）披露关于部分募集资金投资项目变更并将剩余募集资金永久补充流动资金的议案，3月2日股价下跌2.46%
证券之星 · 03-02
万孚生物（300482）披露关于部分募集资金投资项目变更并将剩余募集资金永久补充流动资金的议案，3月2日股价下跌2.46%
万孚生物增资普译生物
视频滚动新闻 · 02-26
万孚生物增资普译生物
暂无数据
公司概况
公司名称：
广州万孚生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-30
主营业务：
广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是传染病检测、慢性疾病检测、妊娠及优生优育检测、毒品(药物滥用)检测。2025年，公司注册获证专利工作实现重大突破，全年共获得产品注册证合计66个，其中NMPA获证51个，CE获证8个，FDA获证4个，MDALL获证3个。新增专利授权33件，累计授权有效专利504件（其中发明专利151件，实用新型专利260件，外观设计93件）。
发行价格：
16.00
{"stockData":{"symbol":"300482","market":"SZ","secType":"STK","nameCN":"万孚生物","latestPrice":18.37,"timestamp":1782105912000,"preClose":19.35,"halted":0,"volume":13276200,"delay":0,"changeRate":-0.0506,"floatShares":430000000,"shares":468000000,"eps":-0.3584,"marketStatus":"交易中","change":-0.98,"latestTime":"06-22 13:25:12","open":19.36,"high":19.4,"low":18.2,"amount":246000000,"amplitude":0.062,"askPrice":18.37,"askSize":13,"bidPrice":18.36,"bidSize":13,"shortable":0,"etf":0,"ttmEps":-0.3584,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782111600000},"marketStatusCode":2,"adr":0,"adjPreClose":19.35,"symbolType":"stock","openAndCloseTimeList":[[1782091800000,1782099000000],[1782104400000,1782111600000]],"highLimit":21.29,"lowLimit":17.42,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":468088698,"isCdr":false,"pbRate":1.67,"roa":"--","roe":"1.54%","epsLYR":-0.13,"committee":0.5,"marketValue":8599000000,"turnoverRate":0.0309,"status":1,"floatMarketCap":7900000000},"requestUrl":"/m/hq/s/300482/tweets","defaultTab":"tweets","newsList":[{"id":"2644572332","title":"股市必读：万孚生物（300482）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644572332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644572332?lang=zh_cn&edition=full","pubTime":"2026-06-18 01:37","pubTimestamp":1781717830,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，万孚生物报收于20.22元，下跌2.46%，换手率5.09%，成交量21.89万手，成交额4.41亿元。董秘最新回复投资者： 请你们及时回复邮箱中投资者关于股东人数的问题，谢谢，公司的对外电话是02032215701吗董秘： 尊敬的投资者您好，您的咨询已回复，请注意查收，感谢您的关注。当日关注点交易信息汇总：6月17日主力资金净流出2390.37万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300482","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643712737","title":"万孚生物涨9.45%，信达证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2643712737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643712737?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:41","pubTimestamp":1781599293,"startTime":"0","endTime":"0","summary":"今日万孚生物涨9.45%，收盘报20.73元。2026年5月6日，信达证券研究员唐爱金发布了对万孚生物的研报《26Q1迎经营拐点，国际化及新产品亮点突出》，该研报对万孚生物给出“买入”评级。研报中预计公司2026-2028年营业收入分别为25.13、28.91、33.35亿元，同比增速分别为20.4%、15.0%、15.4%，实现归母净利润为3.91、4.67、5.63亿元，同比分别增长719.9%、19.4%、20.6%，对应PE分别为22、18、15倍，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600029078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","300482"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642783463","title":"万孚生物涨15.54%，信达证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642783463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642783463?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:52","pubTimestamp":1780995129,"startTime":"0","endTime":"0","summary":"今日万孚生物涨15.54%，收盘报20.45元。2026年5月6日，信达证券研究员唐爱金发布了对万孚生物的研报《26Q1迎经营拐点，国际化及新产品亮点突出》，该研报对万孚生物给出“买入”评级。研报中预计公司2026-2028年营业收入分别为25.13、28.91、33.35亿元，同比增速分别为20.4%、15.0%、15.4%，实现归母净利润为3.91、4.67、5.63亿元，同比分别增长719.9%、19.4%、20.6%，对应PE分别为22、18、15倍，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","300482"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641502116","title":"万孚生物涨15.06%，信达证券四周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2641502116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641502116?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:44","pubTimestamp":1780649046,"startTime":"0","endTime":"0","summary":"今日万孚生物涨15.06%，收盘报18.49元。2026年5月6日，信达证券研究员唐爱金发布了对万孚生物的研报《26Q1迎经营拐点，国际化及新产品亮点突出》，该研报对万孚生物给出“买入”评级。研报中预计公司2026-2028年营业收入分别为25.13、28.91、33.35亿元，同比增速分别为20.4%、15.0%、15.4%，实现归母净利润为3.91、4.67、5.63亿元，同比分别增长719.9%、19.4%、20.6%，对应PE分别为22、18、15倍，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","300482"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911192","title":"万孚生物（300482）披露万孚转债恢复转股提示性公告，6月2日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911192","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640911192?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:48","pubTimestamp":1780393691,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，万孚生物报收于17.41元，较前一交易日下跌1.02%，最新总市值为81.49亿元。该股当日开盘17.65元，最高17.74元，最低17.39元，成交额达6566.04万元，换手率为0.87%。近日，广州万孚生物技术股份有限公司发布公告，公司可转换公司债券“万孚转债”因实施2025年度权益分派，自2026年5月22日至2026年6月1日暂停转股。根据规定，将于权益分派股权登记日后的第一个交易日，即2026年6月2日起恢复转股。公司提醒债券持有人注意相关安排。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200035018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638556552","title":"万孚生物（300482）披露2025年年度权益分派实施公告，5月25日股价上涨0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638556552","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638556552?lang=zh_cn&edition=full","pubTime":"2026-05-25 22:44","pubTimestamp":1779720258,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，万孚生物报收于17.99元，较前一交易日上涨0.22%，最新总市值为84.21亿元。该股当日开盘18.1元，最高18.44元，最低17.97元，成交额达7553.69万元，换手率为0.97%。公司于近日披露《2025年年度权益分派实施公告》。股权登记日为2026年6月1日，除权除息日为2026年6月2日。A股股东现金红利由托管证券公司划入资金账户，部分股东由公司自行派发。本次权益分派实施后，可转债转股价格将相应调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500034255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637251362","title":"万孚生物：公司U-Card DX200配套的微流控芯片系公司自主设计开发及生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2637251362","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637251362?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:33","pubTimestamp":1779420831,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物05月21日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，U-Card DX200仅是检测仪器。此前海外参股布局相关实动作进展如何？万孚生物回复：尊敬的投资者您好，公司U-Card DX200配套的微流控芯片系公司自主设计开发及生产。目前公司已有U-CardDx 200完整的自研微流控芯片体系，而且核心耗材皆为国内供应链，感谢您的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200019194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159813","300482","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637384220","title":"万孚生物（300482）披露关于实施权益分派期间万孚转债暂停转股的提示性公告，5月21日股价下跌1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637384220","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637384220?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:07","pubTimestamp":1779358036,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，万孚生物报收于17.92元，较前一交易日下跌1.05%，最新总市值为83.88亿元。该股当日开盘18.12元，最高18.29元，最低17.88元，成交额达9037.37万元，换手率为1.16%。近日，广州万孚生物技术股份有限公司发布《关于实施权益分派期间万孚转债暂停转股的提示性公告》。公告显示，因实施2025年度权益分派，可转换公司债券“万孚转债”自2026年5月22日起至权益分派股权登记日止暂停转股，恢复转股时间为股权登记日后的第一个交易日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636747021","title":"万孚生物（300482）披露2025年年度股东会会议决议公告，5月18日股价下跌2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636747021","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636747021?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:53","pubTimestamp":1779097994,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，万孚生物报收于18.17元，较前一交易日下跌2.21%，最新总市值为85.05亿元。该股当日开盘18.58元，最高18.78元，最低18.02元，成交额达9231.02万元，换手率为1.18%。万孚生物近日披露《2025年年度股东会会议决议公告》。关联股东对关联交易及董事薪酬议案回避表决。出席会议股东共210人，代表股份占公司有表决权总股份的44.0206%。律师认为会议召集、召开及表决程序合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800028362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634099954","title":"万孚生物涨6.22%，信达证券五日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634099954","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634099954?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:37","pubTimestamp":1778488644,"startTime":"0","endTime":"0","summary":"今日万孚生物涨6.22%，收盘报20.32元。2026年5月6日，信达证券研究员唐爱金发布了对万孚生物的研报《26Q1迎经营拐点，国际化及新产品亮点突出》，该研报对万孚生物给出“买入”评级。研报中预计公司2026-2028年营业收入分别为25.13、28.91、33.35亿元，同比增速分别为20.4%、15.0%、15.4%，实现归母净利润为3.91、4.67、5.63亿元，同比分别增长719.9%、19.4%、20.6%，对应PE分别为22、18、15倍，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","601059"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633890295","title":"万孚生物(300482.SZ)取得一项产品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2633890295","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633890295?lang=zh_cn&edition=full","pubTime":"2026-05-06 15:56","pubTimestamp":1778054188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万孚生物(300482.SZ)发布公告，公司近日收到国家药品监督管理局颁发的医疗器械注册证，涉及产品：“乙型肝炎病毒(HBV)核酸检测试剂盒(PCR-荧光探针法)”。本次公司乙型肝炎病毒核酸检测试剂盒顺利获批上市，是公司分子诊断业务布局的重要里程碑，公司将进一步完善分子诊断业务版图，充实传染病检测产品矩阵，优化整体产品结构与战略布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"万孚生物(300482.SZ)取得一项产品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300482","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637044","title":"万孚生物：万孚新一代高敏肌钙蛋白I检测试剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637044","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631637044?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:51","pubTimestamp":1777553510,"startTime":"0","endTime":"0","summary":"随着高敏肌钙蛋白检测试剂的出现，它能识别更加细微的心肌损伤，更早提示心血管疾病风险。万孚新一代高敏肌钙蛋白I检测试剂第99百分位值的CV＜5%，对表观健康人群的检出率高于95%，被列入国际临床化学与检验医学联合会最新的肌钙蛋白试剂性能参数列表。万孚新一代高敏肌钙蛋白检测试剂不仅具有优秀的临床性能表现，而且检测时间快速，首个结果时间仅需12min，满足急诊胸痛患者对于TAT时间的需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000065979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631570074","title":"万孚生物：POCT业务是公司的基本盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2631570074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631570074?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:34","pubTimestamp":1777520045,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物04月29日在投资者关系平台上答复投资者关心的问题。POCT业务是公司的基本盘，已经有了深厚的市场布局，在此基础上，去年公司也在基层持续铺设荧光平台仪器，公卫基层检测是国内事业部重点覆盖方向，且有医保及财政支持，资金来源有保障。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000039042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631707225","title":"万孚生物：2017年正式进军动物检测市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2631707225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631707225?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:33","pubTimestamp":1777520029,"startTime":"0","endTime":"0","summary":"万孚生物回复：尊敬的投资者您好，2017年，万孚生物正式进军动物检测市场 ，并于2019年成立子公司万德康。成立至今，万德康不断拓展产品线，推出了动物诊断检测设备和试剂等系列产品，为动物临床的多种场景提供体外诊断检测方案。万德康作为万孚生物全资子公司，一直秉持不让生命等候的使命，专注于宠物检测领域，致力于搭建全方位的动物临床一站式检验平台，为动物提供检测诊断整体解决方案，这与宠物大健康的方向是高度重合的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000039020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300482","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629288578","title":"万孚生物（300482）2026年一季报简析：净利润同比下降55.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629288578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629288578?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:38","pubTimestamp":1777041491,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期万孚生物发布2026年一季报。根据财报显示，万孚生物净利润同比下降55.38%。截至本报告期末，公司营业总收入5.82亿元，同比下降27.31%，归母净利润8439.95万元，同比下降55.38%。生意拆解：公司过去三年净经营资产收益率分别为16.7%/20.6%/--，净经营利润分别为4.91亿/5.65亿/-6958.89万元，净经营资产分别为29.48亿/27.44亿/26.73亿元。持有万孚生物最多的基金为东海社会安全，目前规模为0.13亿元，最新净值0.587，较上一交易日下跌0.34%，近一年上涨26.51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400065564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629299500","title":"图解万孚生物年报：第四季度单季净利润同比下降256.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629299500","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629299500?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:02","pubTimestamp":1776877332,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物2025年年报显示，当年度公司主营收入20.87亿元，同比下降31.91%；归母净利润-6302.49万元，同比下降111.22%；扣非净利润-1296.98万元，同比下降102.61%；其中2025年第四季度，公司单季度主营收入3.97亿元，同比下降55.1%；单季度归母净利润-1.97亿元，同比下降256.54%；单季度扣非净利润-9561.13万元，同比下降186.97%；负债率17.09%，投资收益3978.6万元，财务费用4170.1万元，毛利率56.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300002075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629047045","title":"万孚生物（300482）披露召开2025年度股东会的通知，4月22日股价下跌1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629047045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629047045?lang=zh_cn&edition=full","pubTime":"2026-04-22 22:17","pubTimestamp":1776867439,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，万孚生物报收于17.43元，较前一交易日下跌1.08%，最新总市值为81.59亿元。近日，广州万孚生物技术股份有限公司发布《关于召开2025年度股东会的通知》。公告显示，公司定于2026年5月15日召开2025年度股东会，会议由董事会召集，采取现场表决与网络投票相结合的方式；股权登记日为2026年5月12日。其中，第8项和第11项涉及关联交易及董事薪酬，关联股东需回避表决；中小投资者表决将单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200054500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300482","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595486","title":"万孚生物（300482）披露2026年第一季度可转换公司债券转股情况，4月3日股价下跌4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595486","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624595486?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:29","pubTimestamp":1775208556,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，万孚生物报收于17.8元，较前一交易日下跌4.71%，最新总市值为83.32亿元。近日，广州万孚生物技术股份有限公司发布关于2026年第一季度可转换公司债券转股情况的公告。2026年1月1日至3月31日，万孚转债因转股减少210张，对应转股数量为993股。截至2026年3月31日，剩余可转债为5,976,640张，未转换比例为99.61%。公司总股本由468,084,909股增至468,085,902股。公告还列示了可转债发行以来历次转股价格调整情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616553143","title":"万孚生物（300482）披露关于部分募集资金投资项目变更并将剩余募集资金永久补充流动资金的议案，3月2日股价下跌2.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616553143?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:36","pubTimestamp":1772462183,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，万孚生物报收于19.8元，较前一交易日下跌2.46%，最新总市值为92.68亿元。万孚生物于近日披露《2026年第三次临时股东会会议决议公告》。公告显示，公司于2026年3月2日召开2026年第三次临时股东会，审议通过《关于部分募集资金投资项目变更并将剩余募集资金永久补充流动资金的议案》。议案获同意票占出席会议有效表决权股份总数的99.7631%，中小股东同意票占比86.7948%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300482","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614468560","title":"万孚生物增资普译生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2614468560","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614468560?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:50","pubTimestamp":1772106600,"startTime":"0","endTime":"0","summary":"万孚生物(300482)宣布，公司参与了国产纳米孔测序企业普译生物B轮融资，此前，万孚生物还参与了普译生物的A轮融资。普译生物是掌握“纳米孔蛋白-测序芯片-仪器-试剂”全链条核心技术的企业，商业化进展显著。万孚生物表示，将以本轮投资为契机，进一步探索双方在技术融合、渠道协同、场景落地等方面的深度合作。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2026-02-26/doc-inhpcyye7228139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300482","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782105916614,"stockEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0724},{"period":"3month","weight":-0.0075},{"period":"6month","weight":-0.0238},{"period":"1year","weight":-0.0675},{"period":"ytd","weight":-0.008}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州万孚生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41957人(较上一季度增加3.24%)","perCapita":"10250股","listingDate":"2015-06-30","address":"广东省广州市黄埔区科学城荔枝山路8号","registeredCapital":"46808万元","survey":" 广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是传染病检测、慢性疾病检测、妊娠及优生优育检测、毒品(药物滥用)检测。2025年，公司注册获证专利工作实现重大突破，全年共获得产品注册证合计66个，其中NMPA获证51个，CE获证8个，FDA获证4个，MDALL获证3个。新增专利授权33件，累计授权有效专利504件（其中发明专利151件，实用新型专利260件，外观设计93件）。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万孚生物,300482,万孚生物股票,万孚生物股票老虎,万孚生物股票老虎国际,万孚生物行情,万孚生物股票行情,万孚生物股价,万孚生物股市,万孚生物股票价格,万孚生物股票交易,万孚生物股票购买,万孚生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}